Table 5.
Summary of dasatinib treatment received, dose modifications, and discontinuations.
| SM (N=33) | AML (N=9) | MDS/CMML (N=6) | HES (N=5) | CEL (N=3) | PMF (N=11) | |
|---|---|---|---|---|---|---|
|
| ||||||
| Initial dose schedule (N) | ||||||
| 70 mg twice daily | 24 | 9 | 6 | 5 | 3 | 11 |
| 140 mg once daily | 9 | |||||
|
| ||||||
| Median number of treatment cycles (range) | 4 (1–20) | 1 (1–18) | 1 (1–2) | 3 (0–17) | 3 (1–4) | 6 (1–19) |
|
| ||||||
| No. of dose modifications | ||||||
| 0 | 11 | 2 | 2 | 2 | 2 | 7 |
| −1 | 13 | 2 | 2 | 2 | 1 | 3 |
| −2 | 5 | 1 | ||||
|
| ||||||
| Early (<1 month) discontinuation of therapy (N) | 4 (toxicity) | 4 (toxicity 2, progression 1, death 1) | 2 (toxicity 1, comorbid condition 1) | 1 (toxicity) | 1 (toxicity) | |
|
| ||||||
| Off-study due to (N): | ||||||
| Relapse | 4 | 1 | ||||
| Progression | 0 | 2 | 2 | 1 | 1 | |
| Toxicity | 6 | 2 | 2 | 2 | 1 | 1 |
| Death | 2 | 1 | 1 | |||
| No response | 16 | 3 | 1 | 2 | 1 | 10 |